Summary
Calcium channel antagonists are a diverse class of drugs widely used in combination with other therapeutic agents. The potential exists for many clinically significant pharmacokinetic interactions between these and other concurrently administered drugs. The mechanisms of calcium channel antagonist-induced changes in drug metabolism include altered hepatic blood flow and impaired hepatic enzyme metabolising activity. Increases in serum concentrations and/or reductions in clearance have been reported for several drugs used with a number of calcium channel antagonists. A number of reports and studies of calcium channel antagonist interactions have yielded contradictory results and the clinical significance of pharmacokinetic changes seen with these agents is ill-defined. The first part of this article deals with interactions between calcium antagonists and marker compounds, theophylline, midazolam, lithium, doxorubicin, oral hypoglycaemics and cardiac drugs.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
A complete reference list will appear in Part II of this article in the next issue of the journal.
Rights and permissions
About this article
Cite this article
Schlanz, K.D., Myre, S.A. & Bottorff, M.B. Pharmacokinetic Interactions with Calcium Channel Antagonists (Part I). Clin. Pharmacokinet. 21, 344–356 (1991). https://doi.org/10.2165/00003088-199121050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199121050-00003